


REMARKS

In response to the restriction requirement which the Examiner imposed, Applicants elect, with traverse, to prosecute claims 4-10, *i.e.*, the Group II claims. The basis of the traversal is that the examiner has premised the lack of unity on the lack of a special technical feature connecting Groups I and II, citing Nesper *et al.* (2000). However, Nesper *et al.* (2000) relates to the use of whole bacteriophage, not isolated bacteriophage tail proteins, the latter now being recited in all pending claims. Reconsideration of the restriction requirement is therefore requested.

The Examiner is invited to contact the undersigned attorney at 512-536-3184 with any questions, comments or suggestions relating to the referenced patent application.

Respectfully submitted,


Steven L. Highlander
Reg. No. 37,642
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 536-3184

Date: February 28, 2007